{"name":"Zafgen","slug":"zafgen","ticker":"ZFGN","exchange":"NASDAQ","domain":"zafgen.com","description":"Zafgen is a biopharmaceutical company focused on developing treatments for metabolic diseases. The company's lead product, beloranib, was in development for the treatment of obesity and other metabolic disorders. However, the company ceased operations in 2018 and its assets were acquired by a new company, Zafgen Therapeutics. The new company is focused on developing beloranib for the treatment of rare genetic disorders.","hq":"Boston, MA","founded":0,"employees":"","ceo":"Jeffrey Hatfield","sector":"Metabolic Disease Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"$85M","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":154224000,"netIncome":-165673000,"cash":85412000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2019"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"ZGN-433","genericName":"ZGN-433","slug":"zgn-433","indication":"Other","status":"phase_1"},{"name":"ZGN-440","genericName":"ZGN-440","slug":"zgn-440","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"ZGN-433","genericName":"ZGN-433","slug":"zgn-433","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ZGN-440","genericName":"ZGN-440","slug":"zgn-440","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[{"date":"2018-02-26","type":"deal","headline":"Zafgen Announces Sale of Assets to Zafgen Therapeutics","summary":"Zafgen sold its assets to Zafgen Therapeutics, a new company focused on developing beloranib for rare genetic disorders.","drugName":"","sentiment":"neutral"}],"realNews":[{"date":"2026-03-19","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-03-19","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-03-09","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-02-27","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-02-24","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-01-22","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxNXy1TV1JocXBWMUNIX1AwSWotMGVPZHBnaS1YWlpJcGVJYUdsakdyanp5RUFmOTZ0eXVsT0YxWXFtbklEZkQwcUtTU05pRFZOTE5NQ3V1X2ZKeE1VcHFGc2N2RWVyMTlsMGhGNWVlSTkwY09JN19fZWEwSjYzcUFCOW9OTmMtaTZfVkFtV2xrYmhSeDEyeEJzUlFXendnT0hVZjM2dGZBVTlzOTdxTnRTSg?oc=5","date":"2016-04-28","type":"pipeline","source":"Fierce Biotech","summary":"Alizé to advance Prader-Willi drug following PhII completion - Fierce Biotech","headline":"Alizé to advance Prader-Willi drug following PhII completion","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_1":2},"enrichmentLevel":3,"visitCount":3,"keyCompetitors":["Arena Pharmaceuticals","Rhythm Pharmaceuticals","Takeda Pharmaceutical"],"therapeuticFocus":["Metabolic Diseases"],"financials":{"source":"sec_edgar+yahoo","revenue":0,"revenuePeriod":"2019-12-31","revenueHistory":[{"value":0,"period":"2019-12-31"},{"value":0,"period":"2019-09-30"},{"value":0,"period":"2019-06-30"},{"value":0,"period":"2019-03-31"},{"value":0,"period":"2018-12-31"},{"value":0,"period":"2018-09-30"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":154224000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-165673000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":85412000,"cashHistory":[],"totalAssets":145842000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}